Anti-ceramide monoclonal antibody 2A2

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9592238
SERIAL NO

13974405

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH;BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Arap, Wadih Houston, US 58 507
Kolesnick, Richard N New York, US 21 62
Pasqualini, Renata Houston, US 82 1072
Rotolo, Jimmy Andrew New York, US 12 17

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Sep 14, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 14, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00